Share on StockTwits

Investment analysts at Roth Capital lifted their price target on shares of PTC Therapeutics (NASDAQ:PTCT) to $43.00 in a note issued to investors on Monday. Roth Capital’s target price indicates a potential upside of 28.67% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of PTC Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $60.00 price target on the stock. Separately, analysts at Bank of America initiated coverage on shares of PTC Therapeutics in a research note on Tuesday, July 22nd. They set a “buy” rating and a $37.00 price target on the stock. Finally, analysts at Barclays initiated coverage on shares of PTC Therapeutics in a research note on Thursday, July 10th. They set an “overweight” rating on the stock. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $41.58.

PTC Therapeutics (NASDAQ:PTCT) opened at 33.42 on Monday. PTC Therapeutics has a one year low of $13.15 and a one year high of $34.65. The stock has a 50-day moving average of $27.18 and a 200-day moving average of $25.0. The company’s market cap is $980.5 million.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.11. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.71 million. The company’s revenue for the quarter was down 75.5% on a year-over-year basis. On average, analysts predict that PTC Therapeutics will post $-3.47 earnings per share for the current fiscal year.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.